查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1791763

全球类器官与球体市场

Organoids and Spheroids
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 175 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，全球类器官和球状体市场规模将达到 36 亿美元

全球类器官和球状体市场规模预计在2024年达到10亿美元，预计到2030年将达到36亿美元，在分析期内（2024-2030年）的复合年增长率为23.6%。球状体是本报告分析的细分市场之一，预计其复合年增长率将达到25.3%，到分析期结束时规模将达到28亿美元。类器官细分市场在分析期间的复合年增长率预计为18.9%。

美国市场规模估计为 2.661 亿美元，中国市场预计复合年增长率为 22.3%

预计到2024年，美国类器官和球状体市场规模将达到2.661亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到5.488亿美元，2024年至2030年的复合年增长率为22.3%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为21.8%和20.2%。在欧洲，预计德国市场的复合年增长率约为16.1%。

全球类器官和球状体市场—主要趋势和驱动因素摘要

类器官和球体如何彻底改变生物医学研究？

类器官和球状体的开发彻底改变了生物医学研究，提供了比传统二维细胞培养更能模拟人体组织的先进3D模型。这些源自干细胞或原代组织的自组织结构重现了人体器官的结构和功能，已成为药物研发、疾病建模和再生医学的宝贵工具。与传统的单层培养不同，类器官和球状体能够更准确地模拟体内环境，使研究人员能够研究复杂的细胞间相互作用、肿瘤微环境和器官特异性反应。这推动了肿瘤学、神经病学、胃肠病学和个人化医疗领域的突破性进展。

科技创新如何增强类器官和球体的应用？

由于细胞培养技术、生物列印技术和微流体系统的改进，类器官和球状体研究领域正在快速发展。自动化、高通量筛检平台正在加速类器官在大规模药物试验的应用，减少对动物模型的依赖。此外，基于CRISPR的基因编辑技术的整合使得生成患者特异性类器官成为可能，可用于精准医疗。新兴的生物列印技术促进了复杂组织结构的构建，为再生疗法开启了新的可能性。生技公司与学术研究机构之间日益增多的合作，正进一步拓展基于类器官模型的商业化应用。

扩大类器官和球体研究面临的主要挑战是什么？

儘管类器官和球体潜力巨大，但其广泛应用仍面临许多挑战，包括标准化通讯协定的复杂性、高昂的生产成本以及对专业知识的需求。此外，类器官培养可能存在批次间不一致性，导致分化效率和可重复性有差异，仍是一个重大挑战。此外，缺乏针对类器官衍生治疗方法临床应用的监管框架，也对其商业化构成了障碍。为了克服这些挑战，研究人员正在努力改进分化通讯协定、优化培养基配方，并开发用于大规模生产的自动化生物反应器。

是什么推动了类器官和球体市场的成长？

类器官和球状体市场的成长受到多种因素的推动，包括对生理相关疾病模型日益增长的需求、对精准医疗日益增长的关注，以及对动物试验替代方案日益增长的需求。慢性病盛行率的上升以及对有效药物筛检工具的迫切需求，正在加速基于类器官的模型在药物研究中的应用。此外，政府对再生医学和组织工程研究的资助，也促进了利用类器官开发新型治疗方法。器官晶片平台的出现以及人工智慧主导的数据分析技术的进步，进一步推动了市场扩张。

部分

类型（球体、类器官）、应用（发育生物学、个人化医疗、疾病病理学研究、药物毒性和功效测试、再生医学）、最终用途（生物技术和製药最终用途、学术和研究最终用途、医院和诊断中心最终用途）

受访公司范例

  • 3D Biomatrix Inc.
  • 3D Biotek LLC
  • AMSBIO LLC
  • Cellesce Ltd.
  • Corning Incorporated
  • Crown Bioscience Inc.
  • DefiniGEN Limited
  • Emulate Inc.
  • Greiner Bio-One International GmbH
  • Hubrecht Organoid Technology（HUB）
  • InSphero AG
  • Lonza Group AG
  • Merck KGaA
  • Mimetas BV
  • Organovo Holdings Inc.
  • Prellis Biologics Inc.
  • Promega Corporation
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Visikol Inc.

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP32448

Global Organoids and Spheroids Market to Reach US$3.6 Billion by 2030

The global market for Organoids and Spheroids estimated at US$1.0 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 23.6% over the analysis period 2024-2030. Spheroids, one of the segments analyzed in the report, is expected to record a 25.3% CAGR and reach US$2.8 Billion by the end of the analysis period. Growth in the Organoids segment is estimated at 18.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$266.1 Million While China is Forecast to Grow at 22.3% CAGR

The Organoids and Spheroids market in the U.S. is estimated at US$266.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$548.8 Million by the year 2030 trailing a CAGR of 22.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 21.8% and 20.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.1% CAGR.

Global Organoids and Spheroids Market - Key Trends & Drivers Summarized

How Are Organoids and Spheroids Revolutionizing Biomedical Research?

The development of organoids and spheroids has transformed biomedical research, offering advanced 3D models that better mimic human tissues than traditional 2D cell cultures. These self-organizing structures, derived from stem cells or primary tissues, replicate the architecture and functionality of human organs, making them invaluable tools for drug discovery, disease modeling, and regenerative medicine. Unlike conventional monolayer cultures, organoids and spheroids provide more accurate representations of in vivo conditions, allowing researchers to study complex cellular interactions, tumor microenvironments, and organ-specific responses. This has led to groundbreaking advancements in oncology, neurology, gastroenterology, and personalized medicine.

How Is Technological Innovation Enhancing the Application of Organoids and Spheroids?

The field of organoid and spheroid research has witnessed rapid advancements, driven by improvements in cell culture techniques, bioprinting technologies, and microfluidic systems. Automated high-throughput screening platforms have accelerated the adoption of organoids for large-scale drug testing, reducing the reliance on animal models. Additionally, the integration of CRISPR-based gene editing has enabled the creation of patient-specific organoids for precision medicine applications. Emerging bioprinting techniques are facilitating the fabrication of complex tissue structures, opening new possibilities for regenerative therapies. The increasing collaboration between biotechnology firms and academic research institutions is further expanding the commercialization of organoid-based models.

What Are the Key Challenges in Scaling Organoid and Spheroid Research?

Despite their potential, the widespread adoption of organoids and spheroids faces several hurdles, including the complexity of standardized protocols, high production costs, and the need for specialized expertise. The variability in differentiation efficiency and reproducibility remains a major challenge, as organoid cultures can exhibit batch-to-batch inconsistencies. Additionally, the lack of regulatory frameworks governing the clinical application of organoid-derived therapies poses an obstacle to commercialization. To overcome these challenges, researchers are working on refining differentiation protocols, optimizing culture media formulations, and developing automated bioreactors for large-scale production.

What’s Fueling the Growth of the Organoids and Spheroids Market?

The growth in the organoids and spheroids market is driven by several factors, including the increasing demand for physiologically relevant disease models, the expansion of precision medicine initiatives, and the growing need for alternatives to animal testing. The rising prevalence of chronic diseases and the urgent need for effective drug screening tools have accelerated the adoption of organoid-based models in pharmaceutical research. Additionally, government funding for regenerative medicine and tissue engineering research is fostering the development of novel organoid-based therapies. The emergence of organ-on-a-chip platforms and advancements in artificial intelligence-driven data analysis are further propelling market expansion.

SCOPE OF STUDY:

The report analyzes the Organoids and Spheroids market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Spheroids, Organoids); Application (Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application, Regenerative Medicine Application); End-Use (Biotechnology & Pharmaceutical End-Use, Academic & Research Institutes End-Use, Hospitals & Diagnostic Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • 3D Biomatrix Inc.
  • 3D Biotek LLC
  • AMSBIO LLC
  • Cellesce Ltd.
  • Corning Incorporated
  • Crown Bioscience Inc.
  • DefiniGEN Limited
  • Emulate Inc.
  • Greiner Bio-One International GmbH
  • Hubrecht Organoid Technology (HUB)
  • InSphero AG
  • Lonza Group AG
  • Merck KGaA
  • Mimetas B.V.
  • Organovo Holdings Inc.
  • Prellis Biologics Inc.
  • Promega Corporation
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Visikol Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Organoids and Spheroids - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Reliance on 3D Cell Culture Models Drives Adoption of Organoids and Spheroids
    • Shift from Animal Testing to Advanced In Vitro Models Spurs Demand Across Research Applications
    • Rapid Expansion in Oncology Drug Discovery Accelerates Use of Tumor-Derived Organoids
    • Growing Investment in Personalized Medicine Expands Adoption of Patient-Specific Organoids
    • Advancements in Stem Cell and iPSC Technologies Strengthen the Development Pipeline
    • Rising Collaborations Between Biotech and Academia Propel Growth of 3D Culture Platforms
    • Integration of Organoids in Toxicology Testing Generates New Opportunities in Safety Profiling
    • Expansion of CRISPR and Gene Editing Tools Enhances Functional Applications of Organoids
    • Emerging Use in Regenerative Medicine Throws Spotlight on Long-Term Clinical Potential
    • Demand for High-Throughput Screening Systems Drives Innovation in Miniaturized Organoid Models
    • Surge in Biopharma R&D Budgets Sustains Long-Term Growth in Organoid-Based Assays
    • Growing Ethical Concerns in Animal Research Strengthen the Case for Organoid Adoption
    • Adoption of Microfluidic and Lab-on-a-Chip Systems Expands Precision Control in 3D Cultures
    • Rising Application in Neurological and Gastrointestinal Disease Models Diversifies Market Use
    • Emergence of Organoid Biobanks Enhances Commercial and Research Value Chains
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Organoids and Spheroids Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Organoids and Spheroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Organoids and Spheroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Spheroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Spheroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Organoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospitals & Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Biotechnology & Pharmaceutical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Biotechnology & Pharmaceutical End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Developmental Biology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Developmental Biology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Personalized Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Disease Pathology Studies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Disease Pathology Studies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Drug Toxicity & Efficacy Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Drug Toxicity & Efficacy Testing Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Regenerative Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Regenerative Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • JAPAN
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • CHINA
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • EUROPE
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Organoids and Spheroids by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • FRANCE
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • GERMANY
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • UNITED KINGDOM
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030

IV. COMPETITION